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Introduction: Parkinson's disease (PD) is associated with neuropathological changes in olfactory and
gastrointestinal tissues, and PD patients frequently suffer from hyposmia, hyposalivation, and dysphagia.
Since hyposmia and gastrointestinal dysfunction are frequently premotor symptoms, it has been spec-
ulated that an external, for example microbial, agent could trigger the pathologic process in the corre-
sponding organs, subsequently spreading to the central nervous system. We recently showed evidence
for compositional differences between the fecal microbiota of PD patients and control subjects. In this
study, our objective was to explore a possible connection between nasal and oral microbiota and PD.
Methods: We compared the oral and nasal bacterial communities of PD patients (oral: n ¼ 72, nasal:
n ¼ 69) and control subjects (oral: n ¼ 76, nasal: n ¼ 67) using a 16S rRNA gene amplicon sequencing
approach.
Results: Oral and nasal microbiota differed markedly from each other, with no notable similarity within
subjects. Oral microbiota of PD patients and control subjects had differences in beta diversity and
abundances of individual bacterial taxa. An increase in the abundance of opportunistic oral pathogens
was detected in males, both with and without PD. Our data did not reveal convincing differences be-
tween the nasal microbiota of control subjects and PD patients.
Conclusion: The oral microbiome deserves additional research regarding its connection to PD and its
biomarker potential. The higher abundance of oral pathogens in men underlines the importance of
monitoring and promoting male dental health.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Besides motor symptoms, Parkinson's disease (PD) is associated
with a broad spectrum of non-motor symptoms (NMS) that may
precede motor symptoms and severely affect patients' quality of
life. One major aspect of these disturbances is gastrointestinal (GI)
dysfunction [1]. This symptomatology has been linked to alpha-
synuclein related neuropathology in the enteric nervous system
which shows a rostro-caudal gradient with particularly eminent
changes in the salivary glands and the lower esophagus [2].
Recently, comparable changes were found in mucosal sensory
nerve terminals of the oropharynx, larynx, and upper esophagus
[3]. Correspondingly, decreased salivation, notwithstanding therjans).common phenomenon of drooling, and dysphagia are frequently
seen in PD patients [1]. Another early NMS is hyposmia, which is
associated with neuropathological changes in the olfactory system,
and may be present in over 90% of PD patients, often preceding
motor symptoms [4]. The early involvement of olfactory and GI
structures in PD could be compatible with an exogenous factor
acting in the upper respiratory and GI tracts, possibly initiating the
neurodegenerative cascade leading eventually to PD [5]. A micro-
bial aetiology has been discussed in this context, considering the
continuous exposure to external microbes and the thin epithelium
in the nose and enteric organs [6].
Various studies have suggested a potential role for oral micro-
biota in human disease, such as diabetes and cardiovascular disease
[7]. Periodontal diseases are also associated with PD [8]. Based on
our promising ﬁndings regarding gut microbiota in PD [9] and the
strong involvement of olfactory and perioral tissues in early PD, we
carried out a corresponding analysis on nasal and oral samples from
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2. Materials and methods
The study was approved by the ethics committee of the Hospital
District of Helsinki and Uusimaa, and all participants gave informed
consent. The study was registered at clinicaltrials.gov
(NCT01536769).
2.1. Study subjects and sampling
Initially, 152 subjects (76 PD patients and 76 control subjects
with no signs of parkinsonism, frequency-matched for age and
gender) were included in the study. Details on recruitment,
exclusion criteria and clinical data collection have been published
previously [9]. Additionally, we excluded subjects with any known
active chronic disease of the nasal or oral cavity, nasal sinuses,
salivary glands, or pharynx (with the exception of mild allergic or
nonspeciﬁc rhinitis). Periodontal disease or dental caries were not
excluded and patients did not undergo a systematic clinical
assessment of the nasal and oral cavity or dental status. We
excluded patients with a history of major ear, nose or throat (ENT)
surgery (with the following exceptions: enrolment was allowed 6
months after antrostomia, septal surgery, or surgery for obstructive
sleep apnea) and those that reported one or more of the following
in the preceding 2 months: inﬂammation of oral or perioral tissues,
a major dental procedure, more than twice-weekly use of gluco-
corticoids (nasal, inhaled, oral, or parenteral) or intranasal anti-
congestive drugs. None of the subjects had used antibiotics within
the last month nor smoked within the past 6 months.
Nasal and oral samples were obtained with cotton swabs during
clinic visits. For nasal samples, single use sterile nasal specula were
used for insertion of the swab to avoid contact with the nares. The
swab was inserted into the nasal passage between the septum and
middle turbinate aiming towards the upper part of the nasal cavity.
Oral samples were acquired by gently brushing the buccal and
sublingual mucosa bilaterally with the swab. We chose to sample
from these locations due to their close proximity to the oriﬁces of
the submandibular and parotid ducts. Immediately after sampling,
swabs tips were placed into small aliquot containers and in ice.
Within 20 min, samples were transferred to 80 C for storage.
2.2. Sequencing and sequence analysis
The V1-V3 regions of the 16S rRNA gene were ampliﬁed using
universal bacterial primers and sequenced with an Illumina MiSeq
sequencer. Full methodological details are provided in the
Supplement.
Due to technical reasons, the numbers of subjects included in
the ﬁnal oral and nasal sample sets differed: the oral data set
consisted of 72 PD patients and 76 control subjects, while the nasal
data set had 69 PD patients and 67 control subjects. The total
amount of raw reads for the oral data set was 21 645 150, and for
the nasal data set 8 638 162. Raw sequence data have been
uploaded to the European Nucleotide Archive (accession no.
PRJEB14536).
The sequence analysis, including OTU (Operational Taxonomic
Unit) clustering and taxonomy assignment, was done in mothur
[10]. Oligotyping of nasal Staphylococcus sequences was done using
the oligotyping pipeline as instructed by the authors [11]. Full de-
tails are provided in the Supplement.
2.3. Statistics
Statistical analyses were performed using the R statisticalprogramming language. All p-values are double-tailed, with sta-
tistical signiﬁcance accepted at an alpha of 0.05. Non-rareﬁed data
without singletons were used for calculating Shannon and inverse
Simpson alpha diversity indices, which were compared statistically
using Kruskal-Wallis rank sum tests. Beta diversity, based on Bray-
Curtis dissimilarity, was visualized with Non-Metric Multidimen-
sional Scaling (NMDS) and compared statistically with adonis (an
implementation of PERMANOVA) from the vegan package [12].
Differential abundance analyses were done with DESeq2 [13],
which uses Generalised Linear Models with a negative binomial
distribution, with Benjamini-Hochberg method for multiple com-
parison correction. Full details are provided in the Supplement.
3. Results
3.1. Clinical data
The groups were generally similar regarding clinical parameters
(Table 1): gender, age and BMI did not differ signiﬁcantly between
the control and PD groups. As expected, the PD patients had worse
scores for NMS measurements, such as dysphagia assessed by the
Swallowing Disturbance Questionnaire (SDQ) [14], drooling
assessed by the Sialorrhea Clinical Scale for PD (SCS-PD) as a sur-
rogate of saliva volume [15], and hyposmia assessed by the Snifﬁn’
Sticks 16-item smell identiﬁcation test [16]. A history of cholecys-
tectomy was more common in the PD group, and this difference
was statistically signiﬁcant in the nasal data set (p ¼ 0.017), but not
in the larger oral dataset (p¼0.073). All but two PD patients were
using antiparkinsonian medications. Control subjects used more
frequently warfarin and statins than the PD patients, and more
commonly had a history of atrial ﬁbrillation or TIA/ischemic stroke.
3.2. Alpha and beta diversity
The overall alpha diversity (a sample-speciﬁc estimation of di-
versity that quantiﬁes both “species” richness and evenness),
measured with the Shannon and inverse Simpson indices, was
higher in the oral than the nasal data (Kruskal-Wallis rank sum test:
p ¼ 2.12*1010). Statistical comparisons of alpha diversity within
each data set did not suggest any differences between the control
and PD groups (Kruskal-Wallis rank sum test: p > 0.67 for both data
sets; Fig. S1).
Regarding beta diversity (which quantiﬁes community compo-
sition similarity between samples), an ordination plot of Bray-
Curtis dissimilarity visualizing both data sets implied that the
oral and nasal bacterial communities were very distinct, with non-
overlapping clustering by sample location (Fig. 1). Oral and nasal
samples from the same individual did not appear more similar than
those of unrelated subjects (Wilcoxon rank sum test: p ¼ 0.88 for
dissimilarity of oral and nasal microbiota in related vs. unrelated
pairs of samples; Fig. S2).
Beta diversity comparisons with adonis for the oral data sug-
gested a minor but statistically signiﬁcant community difference
between PD patients and control subjects (adonis: p ¼ 0.0138,
R2 ¼ 0.0113) and a borderline difference for gender (adonis:
p ¼ 0.0494, R2 ¼ 0.0098). For the nasal data, there were no statis-
tically signiﬁcant community differences (data not shown).
3.3. Oral microbiota
The oral data set was composed of 7996 non-singleton OTUs,
distributed among 129 genera, 76 families, 41 classes, 23 orders,
and 15 phyla. The most common genera were Streptococcus, Hae-
mophilus, Neisseria, Veillonella and Prevotella (Fig. 2A, Table S1).
Out of the variables used in GLMs (isolation date, gender, age at
Table 1
Clinical data.
Subjects in oral comparisons Subjects in nasal comparisons
control (n ¼ 76) PD (n ¼ 72) p-value control (n ¼ 67) PD (n ¼ 69) p-value
Female sex (%) 50 51.39 0.871 50.75 49.28 1
Age (years, mean ± SD) 64.33 ± 6.95 65.36 ± 5.50 0.317 64.43 ± 6.80 65.25 ± 5.56 0.447
BMI (median, IQR) 26.23 [23.74e28.11] 25.99 [23.72e29.3] 0.946 26.25 [23.89e28.16] 26.25 [24.09e29.16] 0.94
Alcohol units per week (median, IQR) 2 [0e6] 1 [0e5] 0.399 2 [0e5.5] 1 [0e6] 0.796
SDQ total score (median, IQR) 0 [0e1.25] 4 [1.75e8] <0.001 0 [0e2] 3 [1e8] <0.001
SCS-PD total score (median, IQR) 0 [0-0] 2 [1e6] <0.001 0 [0-0] 2 [1e6] <0.001
Snifﬁn’ Sticks score (median, IQR) 13 [12e14] 7 [6e9] <0.001 13 [12e14] 7 [6e9] <0.001
Atrial ﬁbrillation (%) 17.11 4.17 0.016 19.4 4.35 0.008
TIA/ischemic stroke (%) 35.53 5.56 <0.001 37.31 5.8 <0.001
non-major ENT surgery (%) 21.05 22.22 1 20.9 23.19 0.837
Cholecystectomy (%) 3.95 12.5 0.073 1.49 13.04 0.017
Levodopa (%) 0 52.78 <0.001 0 52.17 <0.001
COMT inhibitor (%) 0 13.89 <0.001 0 15.94 <0.001
Dopamine agonist (%) 0 77.78 <0.001 0 79.71 <0.001
MAO inhibitor (%) 0 68.06 <0.001 0 71.01 <0.001
Anticholinergic (%) 0 8.33 0.012 0 8.7 0.028
Warfarin (%) 14.47 1.39 0.005 16.42 1.45 0.002
Statins (%) 53.95 20.83 <0.001 53.73 18.84 <0.001
UPDRS-III; mean ± SD 31.9 ± 8.9 31.8 ± 8.7
UPDRS total (I-IV); mean ± SD 45.9 ± 13.4 46.0 ± 13.4
Years from motor onset; median [IQR] 5 [3e8] 5 [3e8]
Years from NMS onset; median [IQR] 6 [2.5e10.5] 7 [2.75e10.25]
Hoehn and Yahr stage; n (%)
1 4 (5.6%) 3 (4.3%)
1.5 2 (2.8%) 2 (2.9%)
2 23 (31.9%) 23 (33.3%)
2.5 27 (37.5%) 27 (39.1%)
3 16 (22.2%) 14 (20.3%)
PD: Parkinson's disease; SD: Standard Deviation; IQR: interquartile range; BMI: body mass index; SDQ: Swallowing Disturbance Questionnaire [14]; SCS-PD: Sialorrhea
Clinical Scale for PD [15], Snifﬁn' Sticks: Snifﬁn' Sticks 16-item smell identiﬁcation score [16], TIA: transient ischemic attack, ENT: ear, nose and throat, COMT: catechol-O-
methyl transferase, MAO: monoamine oxidase, UPDRS: uniﬁed Parkinson's disease rating scale [17], NMS: non-motor symptoms.
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units per week, SDQ total, SCS-PD total, and control vs PD), control
versus PD was associated with the largest number of differentially
abundant taxa: 11 families, 10 genera and 25 OTUs (Table 2). Many
of the taxa differentially abundant between PD patients and control
subjects (Fig. 2B, Fig. S3, Fig. S4, Table S2) contain potentialFig. 1. Non-metric multidimensional scaling (NMDS) ordination plot of the oral
and nasal samples. Ordination based on Bray-Curtis dissimilarity calculated with
genus-level data, subsampled to 2000 reads per sample. Each point represents one
sample; the closer the points are to one another, the more similar the microbiome
compositions of the samples.opportunistic oral pathogens: Prevotella, Prevotellaceae, Veillonella,
Solobacterium, Veillonellaceae, Lactobacillaceae, and Coriobacter-
iaceae increased in PD, while Capnocytophaga, Rothia, Kingella,
Leptotrichia, Actinomyces, and Leptotrichiaceae decreased. Other
differentially abundant taxa were Haemophilus, Neisseria, Gemella,
Corynebacterium, Granulicatella, an unclassiﬁed Flavobacteriaceae
OTU, Pasteurellaceae, Neisseriaceae, Micrococcaceae, Carnobacter-
iaceae, and Corynebacteriaceae, all found decreased in the PD
group, while Moryella and Erysipelotrichaceae were increased.
Regarding other clinical variables, we found evidence for
increased abundances of taxa containing potential opportunistic
oral pathogens in males relative to females (with or without PD):
Lactobacillus, Capnocytophaga, Leptotrichia, Veillonella, Aggregati-
bacter, Porphyromonas, and Prevotella (Table S3). Age was positively
correlated with Porphyromonas Otu000029 abundance and with an
unclassiﬁed Prevotellaceae OTU, and negatively correlated with the
abundance of Flavobacteriaceae. One taxon with a statistically
signiﬁcant differential abundance was discovered for each of the
other model variables, but further investigation suggested them to
be the result of statistical noise, with the possible exception of
Gemella Otu000162, which was positively correlated with a history
of non-major ENT surgery.3.4. Nasal microbiota
The 2212 non-singleton OTUs of the nasal data represented 553
genera, 177 families, 96 orders, 49 classes, and 28 phyla. The
dominant genus in both subject groups was Corynebacterium,
Fig. 2. Relative abundances of bacterial genera in the control and Parkinson's disease (PD) groups. A. 10 most common genera in the oral data, B. Differentially abundant genera
(DESeq2 p < 0.05) in the oral data. Lower and upper hinge of the box: 1st and 3rd quartile; whiskers: 1.5 * interquartile range; line: median. C. 10 most common genera in the nasal
data.
P.A.B. Pereira et al. / Parkinsonism and Related Disorders 38 (2017) 61e6764followed by the genera Propionibacterium, Moraxella, Staphylo-
coccus and Burkholderia (Fig. 2C, Table S4).
For differential abundance comparisons, the model included
DNA extraction batch, gender, age at sample collection, history of
non-major ENT surgery, Snifﬁn' Sticks score, and control vs PD. A
single taxon was differentially abundant between the control and
PD groups on each of the taxonomic levels explored: Otu00006
(Staphylococcus), the genus Marmoricola, and the family Fla-
vobacteriaceae (Fig. S5, Table S5). To further explore the potentially
interesting Staphylococcus OTU, we performed oligotyping, which
resulted in three oligotypes, none of which appeared differentially
abundant between control subjects and PD patients (Fig. S6;
Supplementary results).
Considering the other variables in the model, DNA extraction
batch and sex were associated with the largest number of differ-
entially abundant taxa, while age at sampling, history of ENT sur-
gery and the Snifﬁn' Sticks score were associated with a handful oftaxa each (Table 2, Table S6). Out of the taxa differentially abundant
for batch or sex, 63 were shared between the two variables, and all
but two of these were more abundant in the second batch and in
female subjects (Fig. S7).4. Discussion
The oral and nasal microbial communities were very different
from one another, with no overlap in the most common taxa, a
higher alpha diversity in the oral data, and distinctive communities
when comparing beta diversity. These results are consistent with
previous studies where oropharyngeal microbiota were found to be
more diverse than nasal microbiota, and more similar in a speciﬁc
anatomical site across individuals than within a speciﬁc individual
[18].
Table 2
Number of differentially abundant (DESeq2 p < 0.05) taxa per variable and taxo-
nomic level. Only variables with at least one differentially abundant taxon are
shown. SCS-PD: Sialorrhea Clinical Scale for PD [15]; ENT: ear, nose and throat; SDQ:
Swallowing Disturbance Questionnaire [14].
Variable Family Genus OTU
Oral
control vs PD 11 10 25
sex 2 10 16
age at sample collection 1 0 2
SCS-PD total 1 0 0
history of ENT surgery 0 0 1
SDQ total 0 0 1
Nasal
DNA extraction batch 41 59 70
sex 24 19 53
age at sample collection 0 1 9
history of ENT surgery 4 3 2
Snifﬁn’ Sticks 0 0 4
control vs PD 1 1 1
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The oral microbial composition inferred from our study is
consistent with previous ﬁndings [19,20]. Streptococcus seems to
dominate the oral communities in virtually all studies, and poten-
tial oral pathogens are widely distributed among subjects,
including orally healthy individuals, supporting the idea that their
pathogenicity is of an opportunistic nature [19].
All members of the Prevotellaceae family that were differen-
tially abundant between control subjects and PD patients in the oral
cavity were increased in PD, as opposed to our ﬁndings regarding
gut microbiota, which showed a reduction in members of this
family in PD cases [9]. This is not contradictory, given that different
species and/or strains can be present in the gut and oral cavity. The
Prevotella genus includes known opportunistic oral pathogens [21],
and it is possible that their increase in PD is associatedwith hygiene
differences, such as motor or non-motor symptoms leading to a
reduction in the efﬁciency of oral care. Lower frequencies of tooth
brushing, less visits to a dentist, as well as an increased prevalence
of caries, periodontal diseases, and tooth loss have been linked to
PD [8]. On the other hand, a recent study reported good self-
assessed dental health care in PD patients [22]. It should also be
noted that in our study, many of the taxa that contain bacteria
associated with oral pathologies were reduced in abundance in PD
(seven out of fourteen OTUs, two out of ﬁve genera, and one out of
ﬁve families). This means that although oral hygiene may play a
partial role, it cannot alone explain the overall differences. Another
potential factor inﬂuencing the oral microbiota could be diet. For
example, gut microbiome studies suggest that Prevotella grows
preferentially on ﬁbre- and carbohydrate-rich diets [23]. PD pa-
tients have been reported to consume more vegetable-derived
proteins and carbohydrates [24], which supports our ﬁndings for
oral Prevotella. However, other studies have suggested that diet
does not signiﬁcantly affect oral microbial communities [25].
Overall, at this point, the reasons for the observed difference in
Prevotella abundance remain unclear and it is premature to decide
whether the detected differences have clinical relevance for PD or
whether some of the taxa could be exploited as biomarkers.
All other taxa with statistically signiﬁcant differential abun-
dances between PD patients and control subjects were found to be
reduced in the PD group, except for Moryella and Erysipelo-
trichaceae, which were increased. However, further investigation
suggests that the statistical signiﬁcance associated with the latter
two taxa is the result of statistical noise. To our knowledge, none of
these groups are recognised as including opportunistic oralpathogens except for Flavobacteriaceae (e.g. Capnocytophaga). Why
these taxa are reduced in abundance in PD is a question that re-
mains open.
The ﬁnding of higher abundances of various genera and families
that contain opportunistic oral pathogens in males, regardless of
disease status, supports studies that indicate worse oral hygiene in
males [26]. This could explain the generalised abundance increase
in these organisms in our study, and may also emphasize the need
to closely monitor dental health, particularly in male PD patients.
Age was positively correlated with Porphyromonas Otu000029
abundance and with the unclassiﬁed Prevotellaceae Otu000438,
and negatively correlated with the abundance of the Flavobacter-
iaceae family. The genus Porphyromonas is associated with peri-
odontal disease (e.g. Porphyromonas gingivalis), as are the
Prevotellaceae and Flavobacteriaceae families, the latter through
Capnocytophaga, which contains various species that are part of the
normal oral microbiome and have pathogenic potential. Visual-
isation of the data suggests that both the Prevotellaceae OTU and
the Flavobacteriaceae familymay be false positives, leaving only the
increase in the Porphyromonas OTU reliably associated with
increasing age. It is possible that this OTU is involved in an increase
in periodontal diseases with increasing age.4.2. Nasal microbiota
The most common genera in our nasal microme samples were
similar to those reported in previous studies [18,27]. Our data did
not offer convincing support for altered nasal microbiota in PD
patients: we did not detect any differences in alpha or beta di-
versity between the control and patient groups. Out of the three
taxa that appeared differentially abundant between control sub-
jects and PD patients, two were less abundant in PD patients: the
genus Marmoricola and the family Flavobacteriaceae. Marmoricola
has only been isolated from environmental sources [28]. Several
genera of the family Flavobacteriaceae include human pathogens,
but for them to be of particular interest, the differential abundance
should be detectable for speciﬁc genera or OTUs. Both taxa could
well be false positives. A Staphylococcus OTUwas more abundant in
PD patients, but further exploration with oligotyping did not sup-
port this difference. It should be mentioned that the mucosal area
closest to the olfactory bulb, the olfactory epithelium, cannot be
reached from the nostrils with non-invasive methods and that the
nasal microbiome may show regional differences. So we cannot
exclude that PD related nasal microbiome alterations could have
been detected if samples had been acquired from the olfactory
epithelium. However, more invasive procedures were beyond the
scope of this exploratory study.
The most prominent differences between nasal samples were
based on DNA extraction batch and sex. The nasal samples were
handled in the order of arrival at the laboratory, which corre-
sponded to the sampling date. This means that seasonal variation
could be one explanation for the differences, but since the samples
collected in the same season were in the same DNA extraction
batch, it is difﬁcult to tell apart technical and seasonal effects. A
particularly puzzling ﬁnding are the 63 taxa that were differentially
abundant in relation to both batch and sex, with a higher abun-
dance in females and in the second of two batches. A recent study
found a difference in bacterial densities in the nares of male and
female subjects, but not in any speciﬁc taxa [29]. One explanation
for our ﬁnding could be that a lower density of bacteria and thus a
lower biomass in female subjects' samples might make reagent
contaminants more prominent. Similar phenomena related to
contamination and the amount of template DNA in PCR have been
reported previously [30].
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Our results support previous studies indicating that oral bacte-
rial communities are more diverse than nasal communities. It also
suggests that the oral microbiota of PD patients differ from those of
control subjects as assessed through beta diversity and differential
abundance analyses. Differences were also detected between sexes,
with a higher abundance of taxa that include opportunistic oral
pathogens in males, which is supported by previous studies
correlating gender and hygiene practices. We did not ﬁnd any in-
dications for differences in nasal microbiota between control sub-
jects and PD patients.
The exploratory nature of this study means that any attempts to
explain the mechanisms behind the connection between PD and
oral microbiotawould be highly speculative, and further research is
needed to gain a better understanding. At this point, we can neither
tell whether oral microbiota are connected to the aetiology of PD,
nor whether the observed changes are a consequence of host
changes associatedwith the disease or the result of external factors.
Regardless of the underlying mechanisms, the detected differences
support further exploration of oral microbiota as a possible
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